(Q42995231)

12 November 2017

0 references

Treatment beyond progression: is it moving from belief to evidence? (English)

1 reference

12 November 2017

Treatment Beyond Progression: Is It Moving from Belief to Evidence? (English)

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0137

13 June 2024

author name string

Rinat Yerushalmi

series ordinal

1

1 reference

12 November 2017

Karen Gelmon

series ordinal

2

1 reference

12 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20671106

13 June 2024

publication date

29 July 2010

1 reference

full work available at URL

12 November 2017

https://europepmc.org/articles/pmc3228025?pdf=render

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20671106/?tool=EBI

13 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20671106/pdf/?tool=EBI

13 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

http://intl-theoncologist.alphamedpress.org/cgi/reprint/15/8/796.pdf

13 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

http://intl-theoncologist.alphamedpress.org/cgi/content/full/15/8/796

13 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

http://intl-theoncologist.alphamedpress.org/cgi/content/abstract/15/8/796

13 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

https://europepmc.org/articles/PMC3228025

13 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

https://europepmc.org/articles/PMC3228025?pdf=render

13 June 2024

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

https://doi.org/10.1634/theoncologist.2010-0137

13 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20671106

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2010-0137

13 June 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0137

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2010-0137

13 June 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0137

https://academic.oup.com/oncolo/article-pdf/15/8/796/41843517/oncolo_15_8_796.pdf

13 June 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.2010-0137

13 June 2024

1 reference

12 November 2017

15

1 reference

12 November 2017

8

1 reference

12 November 2017

796-798

1 reference

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

12 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228025

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20671106

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20671106

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

12 November 2017

1 reference

12 November 2017

1 reference